Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

The efficacy and safety of secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2017-10, Vol.44 (10), p.1129-1137
Hauptverfasser:	Wu, Nan‐Lin, Hsu, Chih‐Jung, Sun, Fang‐Ju, Tsai, Tsen‐Fang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - therapeutic use Asian Continental Ancestry Group Biological Products - therapeutic use Body mass Body mass index Clinical trials Dermatologic Agents - therapeutic use Dose-Response Relationship, Drug Double-Blind Method ERASURE Female Humans Injections, Subcutaneous Interleukin-17 - antagonists & inhibitors interleukin‐17A Male Middle Aged Monoclonal antibodies Patients Pruritus Psoriasis Psoriasis - drug therapy Respiratory tract diseases secukinumab Severity of Illness Index Taiwan Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!